Johnson & Johnson vs. Pfizer: Comparing Healthcare Stocks for 2027
JNJ Johnson & Johnson
$270.47 +1.25%
View chart & analysis → - 1Johnson & Johnson recorded approximately $99.3 billion in revenue for the 12 months ended September 27, 2026.
- 2Pfizer is investing heavily in oncology and obesity pipelines through major acquisitions such as Seagen.
- 3Johnson & Johnson is a more attractive stock than Pfizer as a mature company that has increased dividends annually for over 60 years.
So what's the key point?
Johnson & Johnson has steadily increased its dividends while recording $99.3 billion in revenue. This makes it a more attractive stock than Pfizer.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.